Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib

In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet